Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $8.5 million of Shares

- By insider

CEO of Neurocrine Biosciences Inc (NBIX) Kevin Charles Gorman sold 105,983 shares of NBIX on 02/06/2018 at an average price of $80.25 a share. The total sale was $8.5 million.

Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Neurocrine Biosciences Inc has a market cap of $7.32 billion; its shares were traded at around $82.75 with and P/S ratio of 108.90.


CEO Recent Trades:

  • CEO Kevin Charles Gorman sold 105,983 shares of NBIX stock on 02/06/2018 at the average price of $80.25. The price of the stock has increased by 3.12% since.

  • CEO Kevin Charles Gorman sold 3,750 shares of NBIX stock on 01/16/2018 at the average price of $78.89. The price of the stock has increased by 4.89% since.

Directors and Officers Recent Trades:

  • Chief Commercial Officer Eric Benevich sold 820 shares of NBIX stock on 02/05/2018 at the average price of $83.14. The price of the stock has decreased by 0.47% since.

  • Chief Business Development Off Kyle Gano sold 2,046 shares of NBIX stock on 02/05/2018 at the average price of $83.05. The price of the stock has decreased by 0.36% since.

  • Former Chief Medical Officer Christopher Flint Obrien sold 2,613 shares of NBIX stock on 02/05/2018 at the average price of $83.18. The price of the stock has decreased by 0.52% since.

  • Director Gary A Lyons sold 5,000 shares of NBIX stock on 02/05/2018 at the average price of $83.08. The price of the stock has decreased by 0.4% since.

  • Chief Regulatory Officer Malcolm Lloyd-smith sold 960 shares of NBIX stock on 02/05/2018 at the average price of $83.19. The price of the stock has decreased by 0.53% since.

For the complete insider trading history of NBIX, click here

.This article first appeared on GuruFocus.